A Phase 1b/2 Randomized Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Brief description of study

The goal of the study is to find out if a new drug called LBL-007, given in combination with other drugs called tislelizumab, bevacizumab, and capecitabine, can help people with advanced colon cancer. The study will test this treatment in people who have a certain type of protein called PD-L1, and those who don't have it. The study will also compare the new treatment to another current treatment (bevacizumab in combination with capecitabine) already being used to see which treatment is more effective in helping with advanced colon cancer. This study is for people whose cancer cannot be removed with surgery and has spread to other parts of the body.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.